Scientific aims: To study the role of the human TLR4 (Toll Like Receptor 4) in a number of infectious diseases including sepsis and septic shock, and inflammatory and autoimmune syndromes including neuroinflammatory and neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS (amyotrophic lateral sclerosis).
TOLLerant is then aimed at molecules capable of inhibiting the TLR4. These molecules will be hit and lead compounds to develop drugs targeting diseases in which TLR4 is involved and for which there is still no specific pharmacological treatment and efficient.
This study involves interdisciplinary knowledge in the fields of pharmaceutical and organic chemistry, biochemistry, biophysics, chemistry of nanoparticles, molecular immunology and medicine. The international team of TOLLerant is made up of European researchers of high scientific profile and consolidated international image and with complementary expertise.